Hanmi's New Story
창조와 혁신, 도전
한미약품의 새로운 비상이 시작됩니다.
Meet Us at EASD 2025.
Proteomic analysis of skeletal muscle supporting muscle growth and metabolic improvement effects by HM17321 in diet induced obesity mouse model
- Presentation Number
- 226
- Session
- 39 - OP 39 From muscle to health: growth, atrophy, and adaptation in people with diabetes, Sep 19 at 10:15~10:30 AM
- Presenter
-
Haemin Chon, M.D, Ph.D /
Hanmi Pharmaceutical Co., Ltd
A novel CRFR2 selective UCN2 analogue, HM17321, enhances favourable body recomposition, energy expenditure and metabolic health in DIO mice
- Presentation Number
- 669
- Session
- E - SO 053 Novel mechanisms regulating energy metabolism, Sep 18 at 12:45~13:45 PM
- Presenter
-
Hyunjoo Kwon, Ph.D/
Hanmi Pharmaceutical Co., Ltd
Circulating proteomics analysis reveals potential beneficial effects of HM17321 on muscle and bone
- Presentation Number
- 730
- Session
- A - SO 061 Peripheral mechanisms of glucose metabolism, Sep 16 at 12:00~13:00 PM
- Presenter
-
Haemin Chon, M.D, Ph.D /
Hanmi Pharmaceutical Co., Ltd
Mechanistic insights into the potent anti-obesity effects of HM15275, a novel long-acting GLP-1/GIP/glucagon triple agonist
- Presentation Number
- 765
- Session
- F - SO 066 Novel therapeutics: preclinical evidence for next-generation treatments, Sep 18 at 14:00~15:00 PM
- Presenter
-
Yohan Kim /
Hanmi Pharmaceutical Co., Ltd
Efficacy of the novel UCN2 analogue HM17321 in weight loss without muscle wasting in obese non-human primates and its applications with incretins in obese mice
- Presentation Number
- 819
- Session
- F - SO 072 Next-generation therapeutics: novel approaches to diabetes and obesity, Sep 18 at 14:00~15:00 PM
- Presenter
-
Jeong A Kim, Ph.D /
Hanmi Pharmaceutical Co., Ltd
HM101460, a potent and G protein-biased oral GLP-1R agonist with enhanced bioavailability, exhibits robust efficacy in animal models of type 2 diabetes and obesity
- Presentation Number
- LBA 47
- Session
- B - LBA SO 02 Thinking big about treating obesity, Sep 16 at 13:15~14:15 PM
- Presenter
-
Seohee Kim /
Hanmi Pharmaceutical Co., Ltd
Meet Us at RAS-Targeted Drug Development Summit 2025.
A Novel SOS1-panKRAS Modulator, HM101207: A Promising Combination for Treating KRAS-MAPK Driven Cancers
- Presentation Number
- TBA on the day
- Session
- Poseter Session, Sep 17 at 14:30 PM
- Presenter
-
Jooyun Byun, Ph.D /
Hanmi Pharmaceutical Co., Ltd
Meet Us at ISSX 2025.
Optimization of In vitro-In vivo Extrapolation (IVIVE) Approaches for Human Hepatic Clearance Prediction : Application to EZH1/2 Dual Inhibitor HM97662
- Presentation Number
- P90
- Session
- Poster Session 2, Sep 23 at 12:30~14:30 PM
- Presenter
-
Yunju Kang /
Hanmi Pharmaceutical Co., Ltd
